Repligen (RGEN) Net Income towards Common Stockholders (2010 - 2026)
Repligen's (RGEN) quarterly Net Income towards Common Stockholders came in at $8.4 million in Q1 2026, up 43.6% year-on-year from $5.8 million in Q1 2025, and down 37.17% on a QoQ basis from $13.3 million in Q4 2025.
Repligen (RGEN) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Repligen (RGEN) has 17 years of Net Income towards Common Stockholders data on file, last reported at $8.4 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 43.6% year-over-year to $8.4 million in Q1 2026; TTM through Mar 2026 was $51.5 million, a 232.93% increase from a year earlier, with the FY2025 full-year figure at $48.9 million, up 218.51% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $8.4 million, down from $13.3 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for RGEN reached as high as $49.9 million in Q2 2022 and fell as low as -$49.6 million in Q4 2024.
- Historically, Net Income towards Common Stockholders has averaged $16.0 million across 5 years, with a median of $14.9 million in 2025.
- Across the five-year window, Net Income towards Common Stockholders plunged 1164.41% in 2024 and surged 2380.12% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at $48.7 million in 2022, then tumbled by 90.43% to $4.7 million in 2023, then plunged by 1164.41% to -$49.6 million in 2024, then surged by 126.86% to $13.3 million in 2025, then sank by 37.17% to $8.4 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $8.4 million in Q1 2026, $13.3 million in Q4 2025, and $14.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.32 Bn | 121.10 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 44.69 Bn | 43.88 Bn | 2.15 Bn | -274.00 Mn |
| 3 | Alcon | 32.80 Bn | 31.14 Bn | 1.53 Bn | 22.13 Bn |
| 4 | Medline | 32.72 Bn | 30.49 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 29.54 Bn | 27.88 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 23.56 Bn | 23.13 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 14.00 Bn | 13.44 Bn | 1.10 Bn | 13.00 Mn |
| 8 | Cooper Companies | 13.75 Bn | 13.61 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Align Technology | 12.03 Bn | 10.97 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Repligen | 7.37 Bn | 6.39 Bn | 108.28 Mn | 8.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.37 Mn |
| Dec 31, 2025 | 13.32 Mn |
| Sep 30, 2025 | 14.91 Mn |
| Jun 30, 2025 | 14.87 Mn |
| Mar 31, 2025 | 5.83 Mn |
| Dec 31, 2024 | -49.61 Mn |
| Sep 30, 2024 | -654,000.00 |
| Jun 30, 2024 | 5.71 Mn |
| Mar 31, 2024 | 3.30 Mn |
| Dec 31, 2023 | 4.66 Mn |
| Sep 30, 2023 | 16.92 Mn |
| Jun 30, 2023 | 19.79 Mn |
| Mar 31, 2023 | 28.83 Mn |
| Dec 31, 2022 | 48.73 Mn |
| Sep 30, 2022 | 40.41 Mn |
| Jun 30, 2022 | 49.86 Mn |
| Mar 31, 2022 | 47.35 Mn |
| Dec 31, 2021 | 29.11 Mn |
| Sep 30, 2021 | 33.50 Mn |
| Jun 30, 2021 | 36.23 Mn |